Currenc Group Inc Stock Price, News & Analysis

CURE Pharmaceutical Holding Corp (OTC: CURR) announced a national advertising campaign for its subsidiary Sera Labs' Nutri-Strips product, Sleep A.S.A.P.™. This initiative targets the 70% of American adults experiencing insufficient sleep, coinciding with National Sleep Awareness Month. The global sleep aids market is projected to grow from $81.2 billion in 2020 to $112.7 billion by 2025. The campaign emphasizes Nutri-Strips’ ease of use and scientifically formulated ingredients designed to promote better sleep.

CURE Pharmaceutical Holding Corp. (OTC: CURR) has commenced initial Pharmacokinetics (PK)/bioequivalence studies for its CUREfilm Blue™, an oral film of sildenafil citrate for erectile dysfunction (ED), following approval of an Investigational New Drug (IND) application by the FDA via the 505(b)(2) pathway. The innovative CUREfilm technology aims to enhance patient experience over traditional pills. The global ED drug market is projected to reach approximately USD 6.6 billion by 2025, with sildenafil maintaining a significant market share. This marks a critical step in CURE's clinical development efforts.

CURE Pharmaceutical Holdings (OTC: CURR) announced changes to its Board of Directors, with William Yuan stepping down as Chairman, becoming an advisor and Chairman Emeritus. Rubén José King-Shaw Jr., an executive with extensive healthcare technology experience, has been appointed as the new Chairman. Dov Szapiro has also joined the Board, bringing over 20 years of expertise in the cannabis industry and private investment. CURE aims to leverage this leadership for growth, focusing on its innovative drug delivery technologies and expanding its presence in wellness and endocannabinoid research.

Sera Labs, a subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), has launched ImmunD₃, an oral thin-film strip delivering a weekly dose of 40,000 IU of Vitamin D. This innovation is part of the Nutri-Strips™ line aimed at enhancing convenience in vitamin supplementation. The product is supported by a new e-commerce website and a national TV advertising campaign. Vitamin D's role in immune health is highlighted, with a study indicating that 82.2% of COVID-19 patients were Vitamin D deficient. Sera Labs continues to develop products across health, wellness, beauty, and pets.

CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that CEO Rob Davidson will present at NobleCon17, an institutional investor conference, on January 19 at 3:00 p.m. EST. He will discuss CURE's global health leadership, recent acquisition of Sera Labs, and updates on the approved Investigational New Drug application for CUREfilm Blue™ to treat erectile dysfunction. Davidson emphasized the company's strong distribution and marketing strategies. Attendees can register for the conference for free, and a video of the presentation will be available on CURE's website the next day.

CURE Pharmaceutical Holding Corp (OTC: CURR) announced that CEO Rob Davidson will present at the H.C. Wainwright BioConnect 2021 Virtual Conference on January 11, 2021. The presentation will discuss CURE's acquisition of Sera Labs, enhancing global health and wellness positioning through new distribution channels. Davidson will also highlight the recently approved Investigational New Drug application for CUREfilm Blue™ aimed at treating erectile dysfunction. This event marks a pivotal period for CURE as they expand operations and explore new opportunities.

CURE Pharmaceutical Holding Corp. (OTC: CURR) has received FDA approval for its Investigational New Drug (IND) application for CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This product is being developed using the CUREfilm™ technology, which offers a convenient alternative to traditional pills. The global ED drug market is projected to reach USD $6.6 billion by 2025, presenting significant market potential for CUREfilm Blue™. This milestone validates CURE's technology and opens opportunities for further clinical trials.

CURE Pharmaceutical Holdings (OTCQB: CURR) will present at the LD Micro Main Event Conference on December 15, 2020, at 11:00 AM PT. A video webcast for investors is scheduled for December 17, 2020, at 4:00 PM ET, featuring key executives discussing the company's strategic positioning. Shareholders can submit questions via email by December 15 at 6 PM ET for potential answers during the webcast. Archived versions will also be available post-event. The company focuses on innovative pharmaceutical technology and wellness products, with international partnerships for manufacturing.